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Abstract
Introduction: Sumoylation is involved in nucleolus-nucleoplasm transport of DNA topoisomerase I (topo I), which
may associate with changes of cellular and topo I functions. Skin fibroblasts of patients with systemic sclerosis (SSc)
exhibit profibrotic cellular changes. The aims of this study were to examine the catalytic function and sumoylation
of topo I in the nuclei of SSc fibroblasts, a major cell type involved in the fibrotic process.
Methods: Eleven pairs of fibroblast strains obtained from nonlesional skin biopsies of SSc patients and age/sex/
ethnicity-matched normal controls were examined for catalytic function of nuclear topo I. Immunoprecipitation
(IP)-Western blots were used to examine sumoylation of fibroblast topo I. Real-time quantitative RT-PCR was used
to measure transcript levels of SUMO1 and COL1A2 in the fibroblasts.
Results: Topo I in nuclear extracts of SSc fibroblasts generally showed a significantly lower efficiency than that of
normal fibroblasts in relaxing equivalent amounts of supercoiled DNA. Increased sumoylation of topo I was clearly
observed in 7 of 11 SSc fibroblast strains. Inhibition of SUMO1 with SUMO1 siRNA improved the catalytic efficiency
of topo I in the SSc fibroblasts. In contrast, sumoylation of recombinant topo I proteins reduced their catalytic
function.
Conclusions: The catalytic function of topo I was decreased in SSc fibroblasts, to which increased sumoylation of
topo I may contribute.
Introduction
Systemic sclerosis (SSc) is a human multi-system fibrotic
disease with high morbidity and mortality but the etiol-
ogy is largely unknown and the pathogenesis has yet to
be clearly elucidated. Cutaneous fibrosis is a common
clinical presentation and, based on the extent of skin
involvement, SSc is classified into limited and diffuse
cutaneous forms. The latter subset is characterized by
more rapid progression of skin and visceral involvement,
as well as poorer prognosis [1,2]. Skin fibroblasts
obtained from SSc patients have been found to be profi-
brotic and to synthesize excessive amounts of ECM pro-
teins, which contribute to tissue fibrosis [3]. It is
believed that a possible defect in regulation of biological
functions is present in SSc fibroblasts.
The majority of SSc patients (95%) have autoantibo-
dies against various nuclear, nucleolar and cytoplasmic
proteins, which include non-specific antinuclear antibo-
dies (ANA) and a number of disease specific autoantibo-
dies. Anti-DNA topoisomerase I (topo I) autoantibody is
one of the disease-specific autoantibodies, and it occurs
in 15 to 25% of patients [4-6]. A causal contribution of
anti-topo I to the SSc phenotype is still unclear. There
is no direct evidence indicating pathogenic roles of the
antibodies. On the other hand, there is a strong associa-
tion between anti-topo I autoantibody and the diffuse
cutaneous form of SSc [5,6]. Levels of anti-topo I auto-
antibodies have been reported to correlate with disease
severity and activity in SSc, and the lack of these antibo-
dies conveys a better outcome in SSc [7]. In addition to
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anti-topo I, other SSc specific autoantibodies include
those directed against centromeric proteins (ACA) that
are associated with limited cutaneous disease, RNA
polymerases (I, II and III) (ARA) and fibrillarin that are
associated most often with diffuse skin involvement [8].
Topo I is a monomeric 100 kD nuclear protein that
catalyzes the breaking and joining of DNA strands prior
to transcription [9,10], and is associated with transcrip-
tion, DNA replication and chromatin condensation.
Topo I translocates between the nucleolus and the
nucleoplasm, but is enriched in the nucleolus where
there is a high level of transcription and replication of
the ribosomal DNA [9,10]. Sumoylation is a post-trans-
lational modification, in which the substrates covalently
attach the small ubiquitin-like modifier (SUMO) to
lysine residues. Sumoylation is an important mechanism
in regulating functions of target proteins and has been
associated with the pathogenesis of autoimmune and
inflammatory diseases, such as type I diabetes mellitus
and rheumatoid arthritis [11,12]. Sumoylation of topo I
was reported to facilitate its movement between the
nucleolus and the nucleoplasm [13,14].
The goal of this study was to determine whether there
is abnormal function, distribution and/or sumoylation of
topo I in fibroblasts obtained from SSc patients that




Nonlesional skin biopsies (3 mm punch biopsies) were
obtained from the upper arms of 11 SSc patients with
disease of less than five years duration and 11 age- and
gender-matched normal controls. All SSc patients ful-
filled American College of Rheumatology criteria for SSc
[15], and were positive for ANA. Two patients were
positive for anti-topo I, four for ACA, two for ARA and
one for anti-fibrillarin. Six patients had a diffused form
of SSc, and five had limited SSc. Normal controls were
undergoing dermatologic surgery and had no identified
history of autoimmune diseases. All subjects provided
informed consent and the study was approved by the
Committee for the Protection of Human Subjects at
The University of Texas Health Science Center at
Houston.
Each skin sample was transported in Dulbecco’s Modi-
fied Essential Media (DMEM) with 10% fetal calf serum
(FCS) supplemented with penicillin and streptomycin
for processing the same day. The tissue samples were
washed in 70% ethanol, PBS and DMEM supplemented
with 10% FCS. Cultured fibroblast cell strains were
established by mincing tissues and placing them into 60
mm culture dishes secured by glass coverslips. The pri-
mary cultures were maintained in DMEM with 10% FCS
and supplemented with penicillin and streptomycin. The
early passage (< 5 passages) fibroblast strains were pla-
ted at a density of 2.5 × 105 cells in 35 mm plates and
grown for assays accordingly.
Catalytic function of topo I in SSc fibroblasts
Nuclear proteins were extracted from equal amounts of
the cultured fibroblast cells by using nuclear extract kits
(Active Motif, Carlsbad, CA, USA). The Topoisomerase
I Assay kit (TopoGEN Inc., Port Orange, FL, USA) was
used for measuring the catalytic function of topo I.
Briefly, supercoiled DNA substrate (0.25 μg) (TopoGen,
Inc.) was reacted with nuclear proteins containing topo
I at serial dilutions. After 30-minute incubations at 37°
C, the reaction was terminated with stop buffer (5% Sar-
kosyl, 0.125% bromophenol blue and 25% glycerol). The
reaction mixtures were loaded and electrophoretically
separated on a 1% agarose gel, and then stained with
ethidium bromide. The catalytic activity of topo I was
determined by measuring the intensity of the super-
coiled DNA bands after reactions with a serial dilution
of topo I in the nuclear extract of fibroblasts. A Bio-
imaging system (Gene Genius, Syngene, Frederick, MD,
USA) was used to scan the bands in agarose gel. The
Gene Snap software (Syngene) was used to quantify the
intensity of the bands. A total of 11 pairs of SSc and
control fibroblast strains were examined with this assay.
Immunostaining
SSc and normal fibroblasts were grown in culture media
as described above. After 7, 14 and 18 days, the cells
were washed with PBS and fixed with 100% methanol at
4°C for two minutes. The cells were washed with PBS
again, and incubated with serum from SSc patients
(evenly pooled from four SSc patients) who had positive
anti-topo I autoantibodies, or monoclonal antibodies of
mouse anti-human topo I or mouse anti-human SUMO
1. This was followed by incubation with green fluores-
cent protein (GFP) tagged secondary antibodies (rabbit
anti-human IgG antibodies and anti-mouse antibodies).
Nuclei were visualized by counterstaining DNA with
4’,6-diamidino-2-phenylindole (DAPI) (Vector Labora-
tory Inc., Burlingame, CA, USA). The images of fibro-
blasts with fluorescence labeled proteins were acquired
using fluorescence microscopy (Nikon Eclipse TE2000-
4., Melville, NY. USA).
Western blotting
The protein concentration of nuclear extracts from cul-
tured fibroblasts was measured using the standard curve
in a TECAN spectrophotometer (Tecan Group Ltd.,
Switzerland, 8708 Mannedorf). Equal amounts of pro-
tein from each sample were subjected to SDS-polyacry-
lamide gel electrophoresis. Resolved proteins were
transferred onto nitrocellulose membranes and
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incubated with 1:1,000 diluted primary antibodies
including mouse anti-human topo I (ImmunoVision,
Springdale, AR, USA), anti-human SUMO1 (ABGENT,
San Diego, CA, USA) and anti-collagen type I, individu-
ally. The secondary antibody was a peroxidase-conju-
gated anti-mouse IgG (Amersham, Piscataway, NJ,
USA). Specific proteins were detected by chemilumines-
cence using an Enhanced Chemiluminescence (ECL)
system (Amersham). The intensity of the bands was
quantified using ImageQuant software (Molecular
Dynamics, Sunnyvale, CA, USA).
Immunoprecipitation (IP) Western blotting
Approximately 3.5 × 107 fibroblast cells of each subject
were harvested by trypsinizing the adherent cells and
washed twice with 25 ml ice-cold PBS containing phos-
phatase inhibitors. Cell pellets were then gently resus-
pended by 2 ml hypotonic buffer and nuclear extracts
prepared and measured for protein concentration by a
spectrophotometer as described above. Equal amounts
of protein (500 ug) from each sample were subjected to
immunoprecipitation (IP) with mouse anti-SUMO-1
(GMP1, Invitrogen, Carlsbad, CA, USA) using nuclear
complex co-IP kit (Active Motif, Carlsbad, CA), and
then subjected to SDS-polyacrylamide gel electrophor-
esis. Resolved proteins were transferred onto nitrocellu-
lose membranes and incubated with primary antibodies
of mouse anti-human topo I (ImmunoVision) diluted to
1:1,000. The secondary antibody was a horseradish per-
oxidase-conjugated anti-mouse IgG (eBioscience, San
Diego, CA, USA). Specific proteins were detected by
chemiluminescence using Supersignal West Pico stable
peroxide solution (Thermo Scientific, Rockford, IL,
USA). The intensity of the bands was quantified using
ImageQuant software (Molecular Dynamics).
Inhibition of SUMO1 with siRNA transfection in fibroblasts
SUMO1 siRNAs were purchased from Invitrogen. Three
SSc fibroblast strains that showed stronger sumoylation
of topo I and weaker catalytic topo I function were used
for transfection of SUMO1 siRNA. Briefly, the fibro-
blasts were grown at a density of 1.5 × 105 cells in 25-
cm2 flasks until confluency. The DMEM culture med-
ium in each culture flask was replaced with Opti_MEM
1 (Invitrogen) without FCS. The fibroblasts were trans-
fected with SUMO siRNA using Lipofectamine RNAi-
MAX (Invitrogen) at a concentration of 15 ug/ml. A
fluorescein-labeled non-silencing control siRNA (Qia-
gen, Valencia, CA, USA) was used for detection of
transfection efficiency. After 24 hours, the culture med-
ium was replaced with normal DMEM. The fibroblasts
were examined for gene and protein expression, as well
as topo I catalytic function after 48- or 72-hour
transfection.
Sumoylation assay of topo I
A mixture containing recombinant topo I protein (Topo-
GEN Inc.), SUMO-1 protein (Active Motif), activating
enzyme E1/conjugating enzyme E2 (Active Motif) and
sumoylation buffer (15 mM ATP, 25 mM MgCl2 and
250 mM Tris-HCl) was incubated at 30°C for three
hours. A mutant SUMO-1 protein (Active Motif) lacking
sumoylation function was used as a negative control. The
reaction was stopped with 5 mM EDTA and the recom-
binant human topo I with and without sumoylation were
examined by Western blotting and topo I catalytic assays.
The experiments were performed in triplicate.
Quantitative reverse-transcriptase-polymerase chain
reaction (RT-PCR) for measurement of SUMO1 expression,
as well as COL1A2 expression after SUMO1 siRNA
transfection
The primers and probes of SUMO1, COL1A2, 18S and
GAPDH were obtained from Applied Biosystems
(Assays-on-Demand product line; Foster City, CA,
USA). Total RNA from each sample was extracted from
the cultured fibroblasts described above using a total
RNA kit from OMEGA Biotek (Norcross, GA, USA)
after treatment with DNase I. Complementary DNA
(cDNA) was synthesized using SuperScript II reverse
transcriptase (Invitrogen). Synthesized cDNAs were
mixed with primer/probe of SUMO1 or COL1A2 in 2 ×
TaqMan universal PCR buffer and then assayed on an
ABI Prism 7900 Sequence Detector System (Applied
Biosystems). Each sample was assayed in triplicate. The
data were analyzed with SDS2.2 (ABI). The amount of
each transcript was normalized with 18S and GAPDH
levels.
Measurement of autoantibodies
Patients’ sera were tested for antinuclear antibodies by
indirect immunofluorescence (IIF) using HEp-2 cells as
antigen substrate and fluorescent goat anti-human IgG
as a secondary antibody (Antibodies Inc., Davis, CA,
USA). Anti-topo I antibodies were detected by passive
immunodiffusion kits that employed calf thymus
extracts as the antigen source (INOVA Diagnostics, San
Diego, CA, USA), anti-RNA polymerase III antibodies
were detected by ELISA using commercial kits (MBL,
Nagoya, Japan). Anti-centromere antibodies were deter-
mined visually by their distinctive IIF patterns on HEp-2
cells. Anti-fibrillarin antibodies were detected by immu-
noprecipitation as described previously [16].
Results
Reduced catalytic function of topo I in SSc fibroblasts
After catalytic reactions with a serial dilution of topo I
in the nuclear extracts, the supercoiled DNA band was
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gradually diminished following increased amounts of
topo I in the nuclear extracts. Based on the intensity of
supercoiled DNA bands that were correlated with the
amounts of topo I in the nuclear extracts, the efficiency
of SSc topo I in relaxing the supercoiled DNA appeared
to be less than that of control topo I in each concentra-
tion of nuclear extracts (Figure 1A). Comparison of
average band intensity of remaining supercoiled DNA in
each of six dilutions between all SSc and all control
fibroblasts showed a significant P value (P = 0.0041)
(Student’s t-test) (Figure 1B).
Altered localization of topo I in SSc fibroblasts
When anti-topo I monoclonal antibodies were used as
probes, the majority of SSc fibroblasts from each patient
showed strong nucleoplasmic staining (multiple speck-
les) compared to normal fibroblasts in which topo I
staining was enriched in the nucleolus (Figure 2A). A
few SSc fibroblasts (less than 1%) showed cytoplasmic
(cytosolic) staining which was not observed in normal
fibroblasts. However, there were more SSc fibroblasts
(approximately 2%) showing cytoplasmic staining of
topo I molecules when anti-topo I positive sera from
SSc patients were used as probes (Figure 2B). The cyto-
plasmic staining of topo I appeared to be stronger at 14
or 18 days of culture compared to 7 days.
Altered sumoylation of topo I in SSc fibroblasts
Western blotting showed that the quantitative levels of
topo I proteins were similar between SSc and normal
control fibroblasts, while SUMO 1 levels were increased
in SSc fibroblasts. To validate this finding, we examined
sumoylated topo I in the nuclear proteins using IP Wes-
tern blotting (Figure 3). Increased sumoylation of topo I
(higher intensity of the bands and presence of poly-
sumoylation of topo I) evaluated by IP Western blots
was clearly observed in 7 of 11 SSc fibroblast strains (2
anti-topo I positive patients, 4 anti-RNA polymerase III
positive patients and 1 anti-fibrillarin positive patient
(Figure 3). Interestingly, four SSc fibroblast strains,
including two each from patients with anti-centromere
and with no detectable SSc specific autoantibodies,
Figure 1 Measurement of catalytic function of topo I in cultured fibroblasts. A serial dilution of topo I in the nuclear extracts obtained
from SSc and control fibroblasts was used to relax 0.25 μg supercoiled DNA. A. The supercoiled DNA band is gradually diminished following
increased amounts of topo I in the nuclear extracts in the relaxing assays. The efficiency of SSc topo I in relaxing the supercoiled DNA appeared
to be less than that of control topo I in each concentration of nuclear extracts. B. Comparison of 11 paired SSc and control fibroblasts for mean
values of intensity of supercoiled DNA bands after relaxing assay with different concentrations of topo I in the nuclear extracts. Each P-value of
comparison at different dilution points is listed in the figure. Comparison of average band intensity of remaining supercoiled DNA in each of six
dilutions between all SSc and all control fibroblasts showed a significant P-value (P = 0.0041) (Student’s t-test). A = standard supercoiled DNA
band; B = standard relaxed DNA bands; the numbers (1/32, 1/16, 1/8, 1/4, 1/2 and 1) indicate serial dilutions of topo I in nuclear extracts used
for relaxing supercoiled DNA. The error bars indicate standard deviation (SD).
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showed similar levels of sumoylation as their normal
counterparts.
Inhibition of SUMO1 in SSc fibroblasts increased catalytic
function of topo I
Real-time quantitative RT-PCR showed that inhibition
of SUMO1 with siRNA achieved a significant reduction
of gene expression of SUMO1 (Figure 4). Compared to
non-target siRNA transfected fibroblasts, SUMO1
siRNA transfected fibroblasts showed a 30.97-times
reduction of SUMO1 expression (P < 0.001, T test) (Fig-
ure 4a). Western blots showed a concordant change of
the SUMO1 protein (Figure 4b). Importantly, compared
to either non-target siRNA transfected or non-siRNA
transfected fibroblasts, catalytic function of topo I of
sumo1 siRNA transfected SSc fibroblasts showed a
marked improvement in all three test fibroblast strains
(Figure 5). Measurements of the COL1A2 gene expres-
sion with quantitative RT-PCR and collagen type I pro-
tein expression with Western blots did not show
Figure 2 Comparison of topo I staining in cultured fibroblasts of normal controls and SSc patients. A. Topo I immunostaining with anti-
topo I monoclonal antibodies showed multiple speckles in the nucleoplasm of SSc fibroblasts, which is differentiated from that in normal
fibroblasts (relatively homogenous stain of topo I) at both 7 and 14 days of cultures. Some SSc fibroblasts show cytoplasmic staining of topo I
protein (marked with red arrow heads). B. Topo I immunostaining with anti-topo I positive sera from SSc patients show the expected nuclear/
nucleolar staining as well as cytoplasmic staining of SSc fibroblasts. At Day 14, the cytoplasmic staining appeared to increase relative to the
nucleoplasm and nucleolar staining.
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significant changes after SUMO1 siRNA transfection in
the fibroblasts.
Sumoylation of recombinant topo I decreased its catalytic
function
Recombinant human topo I proteins were sumoylated
with either wild type SUMO1 or mutant SUMO1 or
negative control (without sumoylation) and then were
examined with Western blot for sumoylated topo I and
with topo I catalytic assays for topo I function. Poly-
sumoylation of topo I was observed in the topo I pro-
teins sumoylated with wild type SUMO1 (Figure 6).
Sumoylation of topo I with wild type SUMO1 showed a
reduction of efficiency in catalytic function compared to
the topo I protein sumoylated with mutant sumo 1 or
negative control (Figure 7). The assays were performed
in triplicates, which showed similar results.
Discussion
A novel finding of these studies is the observation that
human SSc fibroblasts have a decreased catalytic func-
tion of topo I. Human topo I plays an important role in
DNA metabolic processes, such as transcription and
replication, in which it releases topological stress in
DNA chains [9,10]. Topo I is generally localized in the
nucleolus where a high level of transcription and repli-
cation of ribosomal DNA occurs. In response to inhibi-
tory factors to topo I, such as camptothecin, UV
irradiation and transcription inhibitors, topo I molecules
were usually relocated from the nucleolus to the nucleo-
plasm due to mechanisms that are not clearly under-
stood. [17-19]. Interestingly, SSc fibroblasts examined
herein showed enhanced staining of topo I in the
nucleoplasm, which suggests a relocation of topo I, and
also supports a reduced function of topo I-associated
DNA metabolic processes.
The cytoplasmic staining of topo I observed in some
SSc fibroblasts was mainly detected by anti-topo I posi-
tive serum from SSc patients and was different from
that found using anti-topo I monoclonal antibodies.
Considering that the polyclonal human sera may contain
mainly a variety of autoantibodies that have non-specific
and antigen specific cross-reactions to cytoplasmic pro-
teins is a possible explanation. With respect to possible
cross-reactions, it is interesting that mitochondrial topo
I has high amino acid homology to nuclear topo I. On
the other hand, it is also possible that the cytoplasmic
staining of topo I may represent ubiquitinated topo I
molecules being processed by cytoplasmic proteasomes.
It is worth noting that the topo I autoantigenic compo-
nent, a 70 kD polypeptide, has been reported to be
Figure 3 Immunoprecipitated Western blots and autoantibody profiles for 11 SSc patients. Each SSc patient (SSc1 to 11) has an age and
sex matched normal control (C1 to 11) for comparison of sumoylated topo I expression with IP Western blots. Poly-sumoylated topo I appeared
in SSc fibroblast strain number 1, 2, 3, 4, 7 and 9. Increased sumoylation of topo I also is observed in the case number 6 compared to its normal
counterpart, but not in the case number 5, 8, 10 and 11. ANA, antinuclear antibodies.
Figure 4 Real-time RT-PCR and Western blots for SUMO1 with
and without SUMO1 siRNA transfection in fibroblasts. Three SSc
fibroblast strains (two with anti-topo I and one with anti-RNA
polymerase III positive serum) were transfected with SUMO1 siRNA.
After 48-hour transfection, total RNAs were used for measuring
SUMO1 transcript levels (Figure 4a), and the nuclear extracts were
used for measuring SUMO1 protein (Figure 4b). Error bars indicate
standard deviation.
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exported via ectocytosis in SSc fibroblasts [20], and anti-
topo I autoantibodies of SSc patients have been shown
to bind to SSc fibroblasts [21].
Sumoylation is an important post-translational modifi-
cation. Previous studies have indicated that sumoylation
of topo I facilitates translocation of topo I protein from
the nucleolus to nucleoplasm [13,14]. Increased sumoy-
lation of topo I in certain SSc fibroblasts observed
herein supports a potential mechanism that may drive
the movement of topo I from the nucleolar compart-
ments to the nucleoplasm where a degradation process
may occur in proteasomes. To further investigate the
association between altered sumoylation and topo I
function in SSc fibroblasts, we inhibited the SUMO1
expression with sequence specific SUMO1 siRNA. Inter-
estingly, SUMO1 inhibition was associated with a favor-
able improvement of the catalytic function of fibroblast
topo I, suggesting that decreased topo I function
observed in SSc fibroblasts may be a result of increased
sumoylation. This possibility was consistent with the fol-
low-up studies of sumoylation of recombinant human
topo I that showed a reduction of catalytic function.
However, sumoylation may not fully explain the reduc-
tion of topo I function in all SSc fibroblasts, especially
in those fibroblasts which did not show the changes of
sumoylation of topo I. These fibroblasts include two
each from patients with ACA and with non-SSc specific
ANAs. In contrast, the fibroblasts from all seven
patients with either anti-topo I ARA or anti-fibrillarin
showed hyper-sumoylation of topo I. All these three
autoantibodies target primary nucleolar proteins. It is
worth noting that the presence of any one of these auto-
antibodies in SSc patients is associated with the diffuse
form of SSc and internal organ fibrosis [8], while the
anti-centromere positive patients usually have a limited
form of SSc with favorable clinical outcomes [8]. Indeed,
all SSc patients examined here with hypersumoylation of
topo I presented as the diffuse form of SSc, except one,
who was positive to ARA, but also clinically had lupus-
like disease and anti-ribonucleoprotein (RNP) autoanti-
bodies. All four SSc patients with unchanged sumoyla-
tion of topo I presented as the limited form of SSc at
the time of skin biopsies. Therefore, sumoylaton of topo
I in SSc fibroblasts appeared to be correlated with the
status of skin fibrosis, which in some SSc patients
changes over time. Recent studies of SSc genetics have
indicated that different genetic susceptibility markers
may determine the types of autoantibodies presenting in
SSc patients [22,23]. The characteristic patterns and spe-
cific genetic associations of SSc autoantibodies suggest
that distinctive mechanisms contribute to different auto-
antibody-associated SSc subsets.
Topo I is an essential functional component of human
cells. Previous reports indicated that knock out of the
topo I gene was associated with death at an early stage
of embryogenesis [24,25]. Inactivation of the topo I gene
in vitro was found to induce genomic instability with
chromosomal aberrations [26]. Inhibition of topo I func-
tion through camptothecin or topotecan (a
Figure 5 Catalytic function of topo I in cultured SSc fibroblasts with and without SUMO1 siRNA transfection. A serial dilution of the
nuclear extract containing topo I obtained from SSc fibroblasts was used to relax 0.25 μg supercoiled DNA. In this figure, the supercoiled DNA
band was completely transformed to relaxed DNA at dilutions of one half and one in the fibroblasts without siRNA transfection or non-target
siRNA transfection. In contrast, this change was observed between the one-eighth and one-fourth dilutions in the fibroblasts with SUMO1
transfection, which indicates a higher efficiency of catalytic function of topo I after SUMO1 inhibition in the fibroblasts. According to the
intensity of the bands of remaining supercoiled DNA in serial dilutions in the assays of three fibroblast strains, these changes are significant. The
P-values are 0.045 and 0.027 at the one-fourth dilution for comparisons between SUMO1 siRNA vs. non-target siRNA, or vs. without siRNA
transfected fibroblasts, respectively (Student’s t-test). This is representative of three SSc fibroblast strains examined in SUMO1 siRNA studies. *A,
supercoiled DNA; B, relaxed DNA.
Figure 6 Western blots show sumoylation of recombinant
human topo I. Recombinant human topo I protein was subjected
to the sumoylation reaction and examined by Western blotting
using anti-topo I (I) and anti-SUMO1 antibodies (II). Compared to
topo I protein without sumoylation reaction (topo I A), topo I
protein with sumoylation reaction (topo I B) showed poly-
sumoylation of topo I (II). The assays showed similar results in
triplicates.
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camptothecin derivative) in human HEp-2 cells altered
nuclear structure and function and targeted topo I for
proteasomal degradation [27]. Although, we do not
know whether sumoylation of topo I in SSc fibroblasts
contributes to any changes of specific antigen binding
or autoantibody presentation in SSc patients, decreased
catalytic function of topo I may alter the nuclear struc-
ture and function of the fibroblasts, which may influence
other nuclear proteins including RNA pol III and fibril-
larin. Of potential significance to our study, topotecan
used therapeutically for cancer has been reported to
induce SSc-like disease [28]. Whether decreased catalytic
function of topo I in SSc fibroblasts examined herein
may result in any consequences associated with patholo-
gical changes in SSc is worthy of further investigations.
Conclusions
In summary, our studies of topo I in SSc fibroblasts
indicate that topo I is functionally altered and is relo-
cated to the nucleoplasm. In some fibroblasts, especially
those obtained from skin biopsies of SSc patients who
were positive for anti-topo I, anti-RNA polymerase III
and anti-fibrillarin autoantibodies, these alterations were
associated with increased sumoylation of topo I. In con-
trast, the fibroblasts of anti-centromere positive patients
showed unchanged sumoylation of topo I. Inhibition of
SUMO1 gene improved catalytic function of topo I in
SSc fibroblasts. These observations may provide impor-
tant insights into the nature of SSc fibroblasts that may
contribute to pathological processes, induction of an
autoimmune response to topo I, and/or disease develop-
ment in SSc.
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